Humanigen, Inc. Class Action Lawsuit - HGEN

(i) Humanigen's lead product candidate, lenzilumab, posed risks to patients in addition to those disclosed by defendants; (ii) lenzilumab was not the only immunomodulator currently in late-stage clinical trials; (iii) lenzilumab was less effective in treating hospitalized COVID-19 patients than defendants had represented; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (v) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the HGEN class action lawsuit, you must have incurred a loss on shares of Humanigen purchased during the class period listed above.

If you suffered a loss in Humanigen during the relevant time frame or pursuant to the relevant offering(s), you have until October 25, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.